Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Poniard gets Fast Track designation for lung cancer treatment
Picoplatin is currently being studied in the pivotal Phase III SPEAR (study of picoplatin efficacy after relapse) trial in small cell lung cancer (SCLC), which is evaluating overall
Picoplatin is currently being studied in the pivotal Phase III SPEAR (study of picoplatin efficacy after relapse) trial in small cell lung cancer (SCLC), which is evaluating overall
Akela says the results demonstrated statistically significant differences compared to placebo in the measured primary and secondary efficacy variables, resulting in faster and superior pain relief. Fentanyl Taifun
The two new indications approved for Cubicin (daptomycin) were right-sided infective endocarditis (RIE) due to staphylococcus aureus (S. aureus), an infection of the heart valve, and S. aureus
The double-blind, placebo controlled cross-over study of two doses of EVT 201 (1.5mg and 2.5mg) in 67 completed patients was conducted in sleep labs in the US using
The data, which included records from October 1997 to June 2005, were generated from a retrospective analysis of a medical database of anonymous patient records entered by general
The trial involved single-ascending-dose, multiple-ascending-dose, food-effect, and drug-interaction studies evaluating RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on
In the study, Provecta will be injected into up to 20 tumors in each subject. Additional treatment with Provecta may be made 8 to 16 weeks after this
The single-arm Phase II trial evaluated a 1800mg/m2 dose of ASA404 in combination with carboplatin and paclitaxel chemotherapy in patients with non-small cell lung cancer. Median survival was
According to Ovation, in previous studies, clobazam was shown to be well tolerated in patients with Lennox-Gastaut syndrome (LGS). The treatment met the primary endpoint in a Phase
<p>The new formulation, using Eurand's Microcaps and AdvaTab technologies, is designed to dissolve quickly in the mouth without leaving a sour or bitter taste. Eurand could potentially receive